When does mepolizumab go off patent?

When does mepolizumab’s patent protection end (and when can competitors enter)?

Mepolizumab’s patent end dates depend on which specific patent (active ingredient, formulation, or method-of-use) is being considered. Patent “off-patent” timing is also different from the date the FDA/EMA grants any marketing exclusivity or the date a generic or biosimilar can actually launch.

DrugPatentWatch tracks this by listing relevant patents and their estimated expiration timelines for mepolizumab. You can use it to check the exact “expires” dates for each patent family that could affect biosimilar entry: DrugPatentWatch – mepolizumab.

How long does patent life usually last—does mepolizumab follow that?

In general, patents are time-limited, and the controlling date is the expiration of the last relevant patent (or, in some cases, the end of any exclusivity tied to regulatory approvals). For biologics like mepolizumab, multiple patents can extend market protection at different times, so “off patent” is rarely a single date.

DrugPatentWatch is the most practical way to identify which specific mepolizumab patents are still active and their expiration dates: DrugPatentWatch – mepolizumab.

What if you meant “biosimilar launch” instead of “patent expiry”?

Even if patents expire, a biosimilar may still face regulatory or exclusivity constraints, and it may choose to delay launch for commercial reasons. To estimate “when biosimilars can compete,” you need both patent timelines and regulatory exclusivity status.

Check the patent list and expiration timing for mepolizumab on DrugPatentWatch, then cross-reference with biosimilar approvals for the same reference product: DrugPatentWatch – mepolizumab.

Sources

1. DrugPatentWatch – mepolizumab